Medical device maker Covidien (NYSE:COV) touted 2-year study results demonstrating the safety and efficacy of its Solitaire FR revascularization system, combating another recently published study that questioned whether devices like Solitaire in provide long-term benefits to stroke patients.
Research & Development
Diabetes: Insulet and Dexcom call it quits on development agreement
Researchers find a genetic marker for aortic valve disease
A team of researchers have pinpointed a gene that may be responsible for double a patient’s risk of calcium buildup in the aortic valve, a condition linked with heart failure, stroke and sudden cardiac death.
The finding may lead to new research and therapies, which are very limited for patients with narrowing, or stenosis, of the aortic valve.
GE Healthcare delves into medical robots
Healthcare giant GE Healthcare (NYSE:GE) is taking a new approach to hospital robotics, aiming to leverage the "Industrial Internet" to develop automated systems that manage surgical tools.
Cordis unveils 2-year trial results for S.M.A.R.T. vascular stent systems
Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. this week unveiled positive 2-year clinical trial results for its S.M.A.R.T. vascular stent systems in treatment of patients with obstructive superficial femoral artery disease.
UnitedHealth, Mayo Clinic in pact to improve patient care
UnitedHealth Group, the largest American health insurer, and the Mayo Clinic are joing up to merge insurance records and medical data to help standardize care and lower costs.
The initiative, including a Mayo/Optum Labs venture announced earlier this week, aims to optimize treatments like hip replacements or medication compliance, according to Veronique Roger, head of Mayo’s Center for the Science of Health Delivery.
Sign up to get our free newsletters delivered right to your inbox.
[sead]
Boston Scientific treats 1st patient in Zero AF trial, aims for FDA win for Blazer catheter
Massachusetts medical device giant Boston Scientific (NYSE:BSX) launched a new study of its Blazer Open-Irrigated Temperature Ablation Catheter, hoping to use the results to win FDA approval.
Diabetes: GI Dynamics inks research deals with Medtronic, GlaxoSmithKline
Covidien unveils ClosureFast ablation study results
Hauser curbs enthusiasm for Boston Scientific’s lead-free implanted defibrillator
Frequent medtech challenger Dr. Robert Hauser offered some words of warning for physicians clamoring over Boston Scientific’s (NYSE:BSX) wire-free implantable defibrillator: curb your enthusiasm.
Early TAVI devices still looking good at 5 years | MassDevice.com On Call
MASSDEVICE ON CALL — Results from the one of the 1st in-human studies of transcatheter aortic valve implants proved that the devices remained durable and effective 5 years after treatment, researchers found.